This site aims to provide an extensive and free-access toolbox to facilitate the professional coverage of Solvay news.
Members of the press can also contact Solvay spokespersons worldwide for further information and assistance.
Latest news
November 17, 2008Solvay Pharmaceuticals discontinues R&D activities of its anti-obesity compound SLV319 Solvay Pharmaceuticals announced today its decision to discontinue all R&D activities for its investigational compound SLV319. [EN]-[FR]-[NL]
November 13, 2008Solvay Group holds 95.33% of Innogenetics shares Solvay will proceed with squeeze-out of remaining Innogenetics shares and request delisting. [EN]-[FR]-[NL]
October 30, 2008Nine months 2008 results Operating results for Solvay Group (EUR 840 million) down by 9% compared to the excellent results of the first nine months 2007. Good resistance in the third quarter (-6%) [EN]-[FR]-[NL]
